Introduction
============

The folate antagonist methotrexate (MTX) is the \'anchor-drug\' in the treatment of patients with rheumatoid arthritis (RA) \[[@B1]\]. The main target of MTX in intracellular folate metabolism is dihydrofolate reductase (DHFR) but several other targets have been described (e.g. thymidylate synthase \[TS\] and 5-amino-imidazole-4-carboxamide ribonucleotide \[AICAR\]). At present the exact mechanism of action of MTX in RA still remains elusive \[[@B1]\]. Despite the potent anti-rheumatic capacity of MTX many patients (at least 50%) become resistant to MTX during long-lasting therapy. However, little is known about the mechanisms of resistance against MTX in RA patients \[[@B2]\].

From the field of oncology, where MTX is used against haematological malignancies, new anti-folate drugs were developed to circumvent MTX resistance \[[@B3]\]. These new folate antagonists have the following characteristics: are better transported through the reduced folate carrier, are retained intracellular more efficiently by polyglutamylation via folylpolyglutamate synthetase, and/or have other targets in the folate pathway besides DHFR (e.g. TS).

Objective
=========

To investigate whether two new-generation anti-folate drugs, PT523 (DHFR-inhibitor) and ZD1694 (TS-inhibitor), have equal or better anti-inflammatory capacity compared with MTX based on their capacity to inhibit tumour necrosis factor alpha (TNF-α) production by activated T cells.

Methods
=======

Whole blood from 11 RA patients and six healthy volunteers was incubated *ex vivo*with MTX, PT523, ZD1694 and, as a control, the DMARD sulphasalazine (SSZ) after T-cell stimulation with α-CD3/CD28. Inhibition of TNF-α production was measured after 72 hours by ELISA \[[@B4]\].

The IC-50 values (defined as the drug concentration exerting 50% inhibition of TNF-α production) are used as a value for the anti-inflammatory capacity of the drug (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of drugs and mean IC-50 values (± standard deviation)

                               Mean IC-50 for TNF-α inhibition   
  -------- ------- ----- ----- --------------------------------- --------------
  MTX      DHFR    ++    \+    78 (77) nM                        57 (27) nM
  PT523    DHFR    +++   \-    5.8 (3.2) nM                      6.4 (8.3) nM
  ZD1694   TS      +++   +++   16 (26) nM                        4.8 (3.0) nM
  SSZ      NF-κB   \-    \-    278 (216) μM                      191 (29) μM

Results
=======

Both PT523 and D1694 turned out to inhibit TNF-α production by activated T cells much more efficiently than MTX (5--15 times). For comparison, the DMARD SSZ is effective at much higher concentration (μM range). The inhibition of TNF-α production by the anti-folate drugs does not seem to be a result of (apoptotic) cell death of T cells whereas SSZ induces apoptosis of T cells (data not shown).

Conclusion
==========

In an *ex vivo*setting, two novel anti-folate drugs designed to circumvent MTX resistance proved to be very effective in inhibiting TNF-α production by activated T cells from RA patients and healthy volunteers. Future experiments are designed to evaluate *ex vivo*anti-folate sensitivity profiles for \'MTX-responders\' and \'MTX-non-responders\' to investigate whether these novel generation of antifolate drugs can be useful in cases of clinical failure on MTX.
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